vimarsana.com
Home
Live Updates
Novartis to prioritise US market, unfazed by drug pricing pu
Novartis to prioritise US market, unfazed by drug pricing pu
Novartis to prioritise US market, unfazed by drug pricing pushback
Novartis aspire to "organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement.
Related Keywords
China ,
Germany ,
Zurich ,
Züsz ,
Switzerland ,
Japan ,
United States ,
Swiss ,
Joe Biden ,
Health Care ,
Swiss Exchange ,
Novartis ,
Inflation Reduction Act ,
Novartis News ,
Partd Drugs ,
Vas Narasimhan ,
Cosentyx ,
Entresto ,
Zolgensma ,
Kisqali ,
Kesimpta ,
Leqvio ,
Pluvicto ,
Scemblix ,
Sandoz ,